Prime Medicine, Inc.
- PRME
- NASDAQ
- Biotechnology
- Gene Editing (Prime Editor)
- Genetic Therapies
$3.47
Today −3.88%Quote Oct 16, 2026, 08:00 PM UTC
+10.51%over the last month
Max drawdown −21.6%From 1-month high −13.0%3 months +13.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$629.4M
Quote Oct 16
Next earnings
Nov 6
Expected, not confirmed
Analyst target
$7.50
+116.1% from here
Floor
$3.46
0.4% below price
Where the price sits
10 analysts
Analyst range, low to high
$6.00$9.00
- Price $3.47
- Resistance $3.55
- Consensus $7.50
The price is just above its floor and right under resistance. Analysts' average target sits about 116% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PRMEPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
146
Founded
2019